Positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in Group 2 PH-HFrEF patients were announced in October 2025, showing TX45 was well tolerated and improved both left heart function and pulmonary hemodynamics. TX2100 advanced into a Phase 1a healthy volunteer clinical trial in February 2026, as a potential treatment for Hereditary Hemorrhagic Telangiectasia (HHT). TX45 advanced into a Phase 2 clinical trial in February 2026, with the first site activated and opened for screening patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD, Group 3 PH). François Nader, M.D., MBA, was appointed as an independent director to the Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Cash and cash equivalents were approximately $253.8 million as of December 31, 2025, which is expected to provide a cash runway into Q4 2028. Net loss for the three months ended December 31, 2025, was $19.2 million, compared to a net loss of $12.4 million for the same period in 2024. Net loss for the full year ended December 31, 2025, was $74.151 million, compared to $57.982 million for the full year 2024.